Allogeneic Hematopoietic Cell Transplantation for Chemotherapy-Unresponsive Mantle Cell Lymphoma: A Cohort Analysis from the Center for International.

Slides:



Advertisements
Similar presentations
Infection Rates among Acute Leukemia Patients Receiving Alternative Donor Hematopoietic Cell Transplantation  Karen Ballen, Kwang Woo Ahn, Min Chen, Hisham.
Advertisements

Impact of Pre-transplant Rituximab on Survival after Autologous Hematopoietic Stem Cell Transplantation for Diffuse Large B Cell Lymphoma  Timothy S.
Outcomes of Hematopoietic Cell Transplantation for Diffuse Large B Cell Lymphoma Transformed from Follicular Lymphoma  Baldeep Wirk, Timothy S. Fenske,
Navneet S. Majhail, Todd DeFor, Hillard M. Lazarus, Linda J. Burns 
Center for International Blood and Marrow Transplant Research Chronic Graft-versus- Host Disease Risk Score Predicts Mortality in an Independent Validation.
Influence of Age and Histology on Outcome in Adult Non-Hodgkin Lymphoma Patients Undergoing Autologous Hematopoietic Cell Transplantation (HCT): A Report.
The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma  Mehdi Hamadani, Erinn Hade, Don M. Benson,
Incidence and Causes of Hospital Readmission in Pediatric Patients after Hematopoietic Cell Transplantation  David Stephen Shulman, Wendy B. London, Dongjing.
Outcomes of Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults with Chronic Myeloid Leukemia: A CIBMTR Cohort Analysis  Sonali.
Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular.
Allogeneic Hematopoietic Cell Transplantation May Alleviate the Negative Prognostic Impact of Monosomal and Complex Karyotypes on Patients with Acute.
Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma  Robert F. Cornell, Anita D'Souza, Adetola.
Impact of Pretransplant Therapy and Depth of Disease Response before Autologous Transplantation for Multiple Myeloma  Ravi Vij, Shaji Kumar, Mei-Jie Zhang,
Survival after T-Cell Replete Haploidentical Related Donor Hematopoietic Cell Transplantation (Haplo-HCT) Using Post-Transplant Cyclophosphamide (PT-CY)
Effect of Obesity on Outcomes after Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma  Dan T. Vogl, Tao Wang, Waleska S. Pérez,
Autologous versus Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Patients with Chemosensitive Follicular Non-Hodgkin Lymphoma beyond.
Hematopoietic Stem Cell Transplantation for Refractory or Recurrent Non-Hodgkin Lymphoma in Children and Adolescents  Thomas G. Gross, Gregory A. Hale,
Allogeneic Hematopoietic Cell Transplantation for Advanced Polycythemia Vera and Essential Thrombocythemia  Karen K. Ballen, Ann E. Woolfrey, Xiaochun.
Navneet S. Majhail, Todd DeFor, Hillard M. Lazarus, Linda J. Burns 
Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia  Hien Duong Liu, Kwang Woo Ahn, Zhen-Huan Hu, Mehdi Hamadani,
Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes.
Assessment of the Hematopoietic Cell Transplantation Comorbidity Index in Non- Hodgkin Lymphoma Patients Receiving Reduced-Intensity Allogeneic Hematopoietic.
Marcelo C. Pasquini, Mei-Jie Zhang, Bruno C
Alternate Donor Hematopoietic Cell Transplantation (HCT) in Non-Hodgkin Lymphoma Using Lower Intensity Conditioning: A Report from the CIBMTR  Gregory.
Carbon Monoxide Diffusion Capacity: How Low Can You Go for Hematopoietic Cell Transplantation Eligibility?  Jason W. Chien, Keith M. Sullivan  Biology.
Allogeneic Hematopoietic Cell Transplantation for Aggressive NK Cell Leukemia. A Center for International Blood and Marrow Transplant Research Analysis 
Allogeneic Hematopoietic Cell Transplantation for Patients with Mixed Phenotype Acute Leukemia  Reinhold Munker, Ruta Brazauskas, Hai Lin Wang, Marcos.
Unrelated Donor Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma  Marcel P. Devetten,
Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia  Hien K. Duong, MD, Mojtaba Akhtari, MD, Kwang Woo Ahn, PhD, Zhen-Huan.
Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Extranodal Natural Killer (Nk)/T-Cell Lymphoma, Nasal Type (ENKL): A CIBMTR Analysis  Abraham.
New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell Transplantation  Anita D'Souza,
Does Total Body Irradiation Conditioning Improve Outcomes of Myeloablative Human Leukocyte Antigen–Identical Sibling Transplantations for Chronic Lymphocytic.
Controversies in Lymphoma: The Role of Hematopoietic Cell Transplantation for Mantle Cell Lymphoma and Peripheral T Cell Lymphoma  Peter Dreger, Ginna.
Risk Factors for Subsequent Central Nervous System Tumors in Pediatric Allogeneic Hematopoietic Cell Transplant: A Study from the Center for International.
Hematopoietic Cell Transplant Comorbidity Index Is Predictive of Survival after Autologous Hematopoietic Cell Transplantation in Multiple Myeloma  Ayman.
Outcome of Lower-Intensity Allogeneic Transplantation in Non-Hodgkin Lymphoma after Autologous Transplantation Failure  César O. Freytes, Mei-Jie Zhang,
Follicular Lymphoma: Prognostic Factors, Conventional Therapies, and Hematopoietic Cell Transplantation  Laurie H. Sehn, Timothy S. Fenske, Ginna G. Laport 
Early Failure of Frontline Rituximab-Containing Chemo-immunotherapy in Diffuse Large B Cell Lymphoma Does Not Predict Futility of Autologous Hematopoietic.
Improvement of Pulmonary Function with Imatinib Mesylate in Bronchiolitis Obliterans Following Allogeneic Hematopoietic Cell Transplantation  Navneet.
Allotransplantation for Patients Age ≥40 Years with Non-Hodgkin Lymphoma: Encouraging Progression-Free Survival  Brian L. McClune, Kwang Woo Ahn, Hai-Lin.
Manish Sharma, Mei-Jie Zhang, Xiaobo Zhong, Muneer H
Outcomes of Patients 65 Years and Older with Non-Hodgkin Lymphoma Receiving Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation.
Adjusting Cyclophosphamide Dose in Obese Patients with Lymphoma Is Safe and Yields Favorable Outcomes after Autologous Hematopoietic Cell Transplantation 
Allogeneic Hematopoietic Cell Transplant for Prolymphocytic Leukemia
Autologous/Allogeneic Hematopoietic Cell Transplantation versus Tandem Autologous Transplantation for Multiple Myeloma: Comparison of Long-Term Postrelapse.
Favorable Overall Survival with Fully Myeloablative Allogeneic Stem Cell Transplantation for Follicular Lymphoma  John Kuruvilla, Gregory Pond, Richard.
Impact of Obesity on Clinical Outcomes of Elderly Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myeloid Malignancies  Ensi Voshtina,
Unrelated Donor Allogeneic Transplantation after Failure of Autologous Transplantation for Acute Myelogenous Leukemia: A Study from the Center for International.
Comparable Outcomes in Nonsecretory and Secretory Multiple Myeloma after Autologous Stem Cell Transplantation  Shaji Kumar, Waleska S. Pérez, Mei-Jie.
Autologous and Allogeneic Transplantation for Burkitt Lymphoma Outcomes and Changes in Utilization: A Report from the Center for International Blood and.
Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for Relapsed and Refractory Mantle Cell Lymphoma (MCL): A Study.
Effect of Body Mass Index on Mortality of Patients with Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation  Willis H. Navarro, Fausto R.
Shigeo Fuji, Hermann Einsele, Bipin N. Savani, Markus Kapp 
Race and Ethnicity Influences Collection of Granulocyte Colony–Stimulating Factor– Mobilized Peripheral Blood Progenitor Cells from Unrelated Donors, a.
Biology of Blood and Marrow Transplantation
Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data  Brent R. Logan, Mei-Jie Zhang,
What is quality in a transplant program?
Outcomes of Human Leukocyte Antigen–Matched Sibling Donor Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia: Myeloablative Versus Reduced-
Athanasios Anagnostopoulos, Parameswaran N. Hari, Waleska S
Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older.
Koen van Besien, Jeanette Carreras, Philip J. Bierman, Brent R
Effect of Postremission Therapy before Reduced-Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia in First Complete Remission 
Patrick J. Stiff, Manza-A. Agovi, Karen H
Recipient Immune Modulation with Atorvastatin for Acute Graft-versus-Host Disease Prophylaxis after Allogeneic Transplantation  Abraham S. Kanate, Parameswaran.
Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: Current Perspectives  Brenda M. Sandmaier, Stephen Mackinnon, Richard.
The Impact of Graft-versus-Host Disease on the Relapse Rate in Patients with Lymphoma Depends on the Histological Subtype and the Intensity of the Conditioning.
Simplified Validated Prognostic Model for Progression-Free Survival after Autologous Transplantation for Hodgkin Lymphoma∗  Theresa Hahn, Philip L. McCarthy,
Salvage Second Hematopoietic Cell Transplantation in Myeloma
Long-Term Results Of Autologous Hematopoietic Cell Transplantation For Peripheral T Cell Lymphoma: The Stanford Experience  Andy I. Chen, Alex McMillan,
Disparities in Utilization of Autologous Hematopoietic Cell Transplantation for Treatment of Multiple Myeloma  Luciano J. Costa, Jia-Xing Huang, Parameswaran.
Presentation transcript:

Allogeneic Hematopoietic Cell Transplantation for Chemotherapy-Unresponsive Mantle Cell Lymphoma: A Cohort Analysis from the Center for International Blood and Marrow Transplant Research  Mehdi Hamadani, Wael Saber, Kwang Woo Ahn, Jeanette Carreras, Mitchell S. Cairo, Timothy S. Fenske, Robert Peter Gale, John Gibson, Gregory A. Hale, Parameswaran N. Hari, Jack W. Hsu, David J. Inwards, Rammurti T. Kamble, Anderas Klein, Dipnarine Maharaj, David I. Marks, David A. Rizzieri, Bipin N. Savani, Harry C. Schouten, Edmund K. Waller, Baldeep Wirk, Hillard M. Lazarus  Biology of Blood and Marrow Transplantation  Volume 19, Issue 4, Pages 625-631 (April 2013) DOI: 10.1016/j.bbmt.2013.01.009 Copyright © 2013 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 Kaplan-Meier estimates of adjusted PFS after allo-HCT for mantle cell lymphoma. Biology of Blood and Marrow Transplantation 2013 19, 625-631DOI: (10.1016/j.bbmt.2013.01.009) Copyright © 2013 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 Kaplan-Meier estimates of adjusted OS after allo-HCT for mantle cell lymphoma. Biology of Blood and Marrow Transplantation 2013 19, 625-631DOI: (10.1016/j.bbmt.2013.01.009) Copyright © 2013 American Society for Blood and Marrow Transplantation Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.